Suvretta Capital Management LLC Has $44.22 Million Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

Suvretta Capital Management LLC decreased its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 33.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,076,448 shares of the company's stock after selling 2,576,334 shares during the period. Kura Oncology comprises about 1.5% of Suvretta Capital Management LLC's investment portfolio, making the stock its 20th biggest holding. Suvretta Capital Management LLC owned about 6.53% of Kura Oncology worth $44,216,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its holdings in Kura Oncology by 11.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock worth $144,000 after acquiring an additional 1,750 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Kura Oncology by 2.0% during the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock valued at $871,000 after buying an additional 1,923 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Kura Oncology by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock valued at $120,000 after buying an additional 2,285 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Kura Oncology by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 44,828 shares of the company's stock valued at $390,000 after buying an additional 2,776 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after buying an additional 3,061 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have recently weighed in on KURA. Wall Street Zen cut Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Mizuho cut their price target on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday. Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a research note on Monday, April 28th. Finally, UBS Group dropped their target price on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Kura Oncology currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.50.

Kura Oncology Price Performance

Kura Oncology stock traded up $0.09 during mid-day trading on Thursday, hitting $6.29. 247,502 shares of the company were exchanged, compared to its average volume of 1,182,247. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $23.48. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $6.35 and a 200 day moving average of $8.61. The company has a market capitalization of $544.12 million, a PE ratio of -2.66 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. As a group, sell-side analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.